GLP1R and Hepatic fibrosis: The adjustment for age and BMI (model 1) or for the baseline use of some specific glucose-lowering agents, such as glucagon-like peptide 1 (GLP-1) receptor agonists (model 2), sodium-glucose cotransporter-2 (SGLT2) inhibitors (model 3) or pioglitazone (model 4) that might favourably affect NAFLD and liver fibrosis did not weaken the strength of this association.